Evidence that independent gut-to-brain and brain-to-gut pathways operate in the irritable bowel syndrome and functional dyspepsia: a 1-year population-based prospective study

Alimentary Pharmacology and Therapeutics

Volumn 44, Issue 6, 2016, Pages 592-600

  Koloski, N A ^a   Jones, M ^b   Talley, N J ^a  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b MACQUARIE UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANXIETY; ARTICLE; AUSTRALIA; BRAIN FUNCTION; DEPRESSION; DISTRESS SYNDROME; DYSPEPSIA; FEMALE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; INCIDENCE; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; POPULATION RESEARCH; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOLOGIC ASSESSMENT; QUALITY OF LIFE; QUESTIONNAIRE;

EID: 84981164813     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13738     Document Type: Article

References (48)

1. Koloski NA, Talley NJ, Boyce PM. Epidemiology and health care seeking of the functional gastrointestinal disorders. A population-based study. Am J Gastroenterol 2002; 97: 2290–9.
2. Foundation Rome. Guidelines-Rome III diagnostic criteria for functional gastrointestinal disorders. J Gastrointest Liver Dis 2006; 15: 307–12.
3. Koloski NA, Jones M, Kalantar J, et al. The brain-gut pathway in functional gastrointestinal disorders is bidirectional: a 12-year prospective population-based study. Gut 2012; 61: 1284–90.
4. Keightly PC, Koloski NA, Talley NJ. Pathways in gut-brain communication: evidence for distinct gut-to-brain and brain-to-gut syndromes. Aust New Zealand J Psychiatr 2015; 49: 207–14.
5. Addolorato G, Mirijello A, D'Angelo C, et al. State and trait anxiety and depression in patients affected by gastrointestinal diseases: psychometric evaluation of 1641 patients referred to an internal medicine outpatient setting. Int J Clin Pract 2008; 62: 1063–9.
6. Koloski NA, Talley NK, Boyce PM. Somatization an independent psychosocial risk factors for irritable bowel syndrome but not dyspepsia: a population-based study. Eur J Gastroenterol Hepatol 2006; 18: 1101–9.
7. Talley NJ, Boyce PM, Jones M. Predictors of health care seeking for irritable bowel syndrome: a population based study. Gut 1997; 41: 394–8.
8. Aro P, Talley NJ, Ronkainen J, et al. Anxiety is associated with uninvestigated and functional dyspepsia (Rome III Criteria) in a Swedish Population-Based Study. Gastroenterology 2009; 137: 94–100.
9. Boyce P, Talley NJ, Balamm B, et al. A randomised control trial of cognitive behaviour therapy, relaxation therapy and routine clinical care for the irritable bowel syndrome. Am J Gastroenterol 2003; 98: 2209–18.
10. Ford AC, Quigley EM, Lacy BE, et al. Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 2014; 109: 1350–56.
11. Dickhaus B, Mayer EA, Firooz N, et al. Irritable bowel syndrome patients show enhanced modulation of visceral perception by auditory stress. Am J Gastroenterol 2003; 98: 135–43.
12. Dorn SD, Palsson OS, Thiwan SI, et al. Increased colonic sensitivity in irritable bowel syndrome strongly influenced by a psychological tendency to report pain and urge. Gut 2007; 56: 1202–9.
13. Silverman DH, Munakata JA, Ennes H, et al. Regional cerebral activity in normal and pathological perception of visceral pain. Gastroenterology 1997; 112: 64–72.
14. Lorena SL, Tinois E, Brunetto SQ, et al. Gastric emptying and intragastric distribution of a solid meal in functional dyspepsia: influence of gender and anxiety. J Clin Gastroenterol 2004; 38: 230–6.
15. Liebregts T, Bredack AB, Roth A, et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology 2007; 132: 913–20.
16. Liebregts T, Adam B, Bredack C, et al. Small bowel homing T cells are associated with symptoms and delayed gastric emptying in functional dyspepsia. Am J Gastroenterol 2011 Jun; 106: 1089–98.
17. Adam B, Tsopelas C, Liebregts T, Bartholomeusz FD, Holtmann G. Host immune response determines visceral hyperalgesia in a rat model of post-inflammatory irritable bowel syndrome. J Gastroenterol 2013; 48: 1119–27.
18. Jones M, Van Oudenhove L, Talley NJ. Functional gastrointestinal disorders (FGIDs) and psychological disorders: strong evidence that the link is bidirectional but psychological distress is more likely to precede a new diagnosis of an FGID. Digestive Diseases Week 2012. Gastroenterology 2012; 142: S1–570.
19. Bercik P, Denou E, Collins J, et al. The intestinal microbiota affect central levels of brain-derived neurotropic factor and behavior in mice. Gastroenterology 2011; 141: 599–609.
20. Keely S, Walker MM, Marks E, Talley NJ. Immune dysregulation in the functional gastrointestinal disorders. Eur J Clin Invest 2015; 45: 1350–59.
21. Talley NJ, Ford AC. Functional dyspepsia. N Engl J Med 2015; 373: 1853–63.
22. Locke GR 3rd, Weaver AL, Melton LJ 3rd, Talley NJ. Psychosocial factors are linked to functional gastrointestinal disorders: a population based nested case-control study. Am J Gastroenterol 2004; 99: 350–7.
23. Whitehead WE, Palsson OS, Thiwan SIM, et al. Development and validation of the Rome III diagnostic questionnaire. In Drossman DA, Corazziari E, Delvaux M, eds. Rome III: The Functional Gastrointestinal Disorders, 3rd ed. McLean, VA: Degnon Associates, 2006; 835–53.
24. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression scale. Acta Psychiatr Scand 1983; 67: 361–70.
25. Ware JE, Kosinski M, Keller SD. SF-12: How to Score the SF-12 Physical and Health Summary Scales. Boston: The Health Institute, New England Medical Center, 1999.
26. Dillman DA. Mail and Telephone Surveys: The Total Design Method. New York: John Wiley, 1978.
27. Larsson MB, Tillisch K, Craig AD, et al. Brain responses to visceral stimuli reflect visceral sensitivity thresholds in patients with irritable bowel syndrome. Gastroenterology 2012; 142: 463–72.
28. Van Oudenhove L, Vandenberghe J, Dupont P, et al. Regional brain activity in functional dyspepsia: a H(2)(15)O-PET study on the role of gastric sensitivity and abuse history. Gastroenterology 2010 Jul; 139: 36–47.
29. Johannesson E, Simrén M, Strid H, Bajor A, Sadik R. Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial. Am J Gastroenterol 2011; 106: 915–22.
30. Cross-Adame E, Rao SS. Brain and gut interactions in irritable bowel syndrome: new paradigms and new understandings. Curr Gastroenterol Rep 2014; 16: 379.
31. Hirsh AT, George SZ, Bialosky JE, et al. Fear of pain, pain catastrophizing, and acute pain perception: relative prediction and timing of assessment. J Pain 2008; 9: 806–12.
32. Posserud I, Svedlund J, Wallin J, et al. Hypervigilance in irritable bowel syndrome compared with organic gastrointestinal disease. J Psychosom Res 2009; 66: 399–405.
33. Simen BB, Duman CH, Simen AA, et al. TNFalpha signalling in depression and anxiety: behavioral consequences of individual receptor targeting. Biol Psychiatry 2006; 59: 775–85.
34. Matricon J, Meleine M, Gelot A, et al. Review article: associations between immune activation, intestinal permeability and the irritable bowel syndrome. Aliment Pharmacol Ther 2012; 36: 1009–31.
35. Sudo N, Chida Y, Aiba Y, et al. Postnatal microbial colonization programs the hypothalamic–pituitary–adrenal system for stress response in mice. J Physiol 2004; 558: 263–75.
36. Desbonnet L, Garrett L, Clarke G, et al. Effects of the probiotic bifidobacterium infantis in the maternal separation model of depression. Neuroscience 2010; 170: 1179–88.
37. Diaz Heijtz R, Wang S, Anuard F, et al. Normal gut microbiota modulates brain development and behavior. Proc Natl Acad Sci USA 2011; 108: 3047–52.
38. Neufeld KM, Kang N, Bienenstock J, et al. Reduced anxiety like behavior and central neurochemical change in germ-free mice. Neurogastroenterol Motil 2011; 23: 255–64.
39. Cremon C, Carini G, De Giorgio R, et al. Intestinal dysbiosis in irritable bowel syndrome: etiological factor or epiphenomenon? Expert Rev Mol Diagn 2010; 10: 389–93.
40. Sundin J, Rangel I, Fuentes S, et al. Altered faecal and mucosal microbial composition in post-infectious irritable bowel syndrome patients correlates with mucosal lymphocyte phenotypes and psychological distress. Aliment Pharmacol Ther 2014; 41: 342–51.
41. Collins SM, Surette M, Bercik P. The interplay between the intestinal microbiota and the brain. Nat Rev Microbiol 2012; 10: 735–42.
42. Pimentel M, Lembo A, Chey WD, et al. TARGET Study Group. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011; 364: 22–32.
43. Mayer EA, Savidge T, Shulman RJ. Brain-gut microbiome interactions and functional bowel disorders. Gastroenterology 2014; 146: 1500–12.
44. DuPont HL. Review article: the antimicrobial effects of rifaximin on the gut microbiota. Aliment Pharmacol Ther 2015; 43: 3–10.
45. Keely S, Walker MM, Marks E, Talley NJ. Immune dysregulation in the functional gastrointestinal disorders. Eur J Clin Invest 2015; 45: 1350–9.
46. Talley NJ, Holtmann G, Walker MM. Therapeutic strategies for functional dyspepsia and irritable bowel syndrome based on pathophysiology. J Gastroenterol 2015; 50: 601–13.
47. Snaith RP. The hospital anxiety and depression scale. Health Qual Life Outcomes 2003; 1: 29.
48. Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res 2002; 52: 69–77.